Estrogen Therapy Contraindications in Women with Transient Ischemic Attack History

Guideline-Based Contraindication

• The American Heart Association and American Stroke Association explicitly state that postmenopausal hormone therapy (estrogen with or without progestin) is not recommended for women who have had ischemic stroke or TIA (Class III recommendation, Level of Evidence A) 1
• The American Heart Association and American College of Cardiology recommend that HRT should not be initiated for secondary prevention in women with a history of cardiovascular events, including TIA, due to the potential harm it may cause in this population 1

Evidence of Harm in Women with Prior Cerebrovascular Events

• The Women's Estrogen for Stroke Trial (WEST) found no reduction in stroke recurrence or death over 2.8 years of follow-up in postmenopausal women with prior stroke or TIA who received estradiol versus placebo 1
• The Women's Estrogen for Stroke Trial (WEST) found a higher risk of fatal stroke in the estrogen group (HR 2.9; 95% CI 0.9-9.0) in postmenopausal women with prior stroke or TIA 1
• The Women's Estrogen for Stroke Trial (WEST) found worse functional outcomes after recurrent strokes in women taking estrogen who had prior stroke or TIA 1

Critical Clinical Pitfall

• The American Heart Association and American College of Cardiology state that the cardiovascular and cerebrovascular risks of estrogen apply regardless of the indication for its use, and a history of TIA represents an absolute contraindication that supersedes any potential benefits for treating amenorrhea 1, 2

HRT Initiation and Cardiovascular Considerations

Contraindications for HRT Initiation

• The American Heart Association recommends that HRT should not be initiated for secondary prevention in women with a history of cardiovascular events, such as myocardial infarction, stroke, or transient ischemic attack 3, 4
• The American College of Cardiology states that HRT is contraindicated in women with a history of cardiovascular events, regardless of bleeding evaluation results 3, 4

Contraindication of Transdermal Estrogen After Transient Ischemic Attack

Guideline Recommendations

• The American Heart Association/American Stroke Association issue a Class III recommendation (Level A evidence) that post‑menopausal hormone therapy—estrogen alone or combined with progestin—should not be used in women with a prior ischemic stroke or TIA because the intervention is ineffective and may be harmful. 5

Clinical Trial Evidence of Harm

• The Women’s Estrogen for Stroke Trial (WEST) enrolled 664 post‑menopausal women with a previous stroke or TIA, randomizing them to estradiol or placebo for a mean of 2.8 years. The trial showed:

  • No reduction in stroke recurrence or all‑cause death (relative risk = 1.1; 95 % CI 0.8–1.4).
  • Higher risk of fatal stroke in the estradiol group (hazard ratio = 2.9; 95 % CI 0.9–9.0).
  • Worse functional outcomes after recurrent strokes among women receiving estrogen.

• The Women’s Health Initiative (WHI) primary‑prevention trials (large randomized studies) demonstrated that hormone therapy increases stroke risk:

  • Estrogen + progestin: hazard ratio = 1.44 (95 % CI 1.09–1.90).
  • Estrogen alone: hazard ratio = 1.53 (95 % CI 1.16–2.02).

Applicability Across Formulations and Timing

• The guideline contraindication applies to all estrogen formulations, including transdermal preparations, because the underlying harm demonstrated in the WEST trial is not expected to differ by route of administration. 5

• The contraindication is universal regardless of how long ago the TIA occurred; both recent and remote TIAs trigger the same Class III recommendation. 5